CBI

Leading life science success

CBI is Israel’s largest life sciences holding company

about cbi

Clal Biotechnology Industries (TASE: CBI) is Israel’s leading life sciences investment company. CBI supports life sciences by identifying and powering science backed ventures and proactively guiding them to transform the healthcare industry.

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on the fields of severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Lead product, NiCord® is currently in phase III clinical trial in hematological malignancies.
+

Anchiano (formerly Biocancell)

Anchiano Therapeutics (TASE: ANCN) is a clinical stage biopharmaceutical company dedicated to developing new therapies for non-muscle-invasive bladder cancer.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer
+

Neon Therapeutics

Neon Therapeutics (Nasdaq: NTGN) is a clinical stage, immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.
+

Cadent Therapeutics

Cadent Therapeutics is developing novel drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
+

Biokine

Biokine Therapeutics is company focused on developing novel therapeutics to treat cancer. It's lead product, BL-8040, is licensed to BiolineRx and is in phase III clinical development.

See complete portfolio

Press Releases

2020

21

Sep

Elicio Therapeutics: Collaboration with Moffitt Cancer Center to Study AMP-CD19 in Combination with CD19 CAR T cells
21

Sep

eXIthera: Publication of EP-7041 Data; Will Pursuit 2 Parallel EP-7041 Indications, in ECMO and in COVID-19
16

Sep

MediWound: FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
10

Sep

Gamida Cell: Analysis of Observational Data Demonstrating the Impact of Donor Age on Hematopoietic Stem Cell Transplant Outcomes
08

Sep

Pi-Cardia: Initiation of a Leaflex™ Clinical Trial in Severe Aortic Stenosis
06

Sep

Elicio Therapeutics: A $15 Million Funding

Read all Press Releases